

Oncology Today with Dr Neil Love: Adjuvant Therapy for ER-Positive Breast Cancer (Interview Audio)**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following statements is true regarding the monarchE trial evaluating the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative early breast cancer?**
 - a. Eligible patients were at high risk of recurrence
 - b. No improvement was reported in invasive disease-free survival with abemaciclib
- 2. The Phase III PALLAS trial evaluating the addition of palbociclib to adjuvant endocrine therapy demonstrated which of the following outcomes in the primary endpoint of invasive disease-free survival on the palbociclib arm?**
 - a. A significant improvement in invasive disease-free survival
 - b. No significant improvement in invasive disease-free survival
- 3. Which of the following statements is FALSE regarding the diarrhea associated with the CDK4/6 inhibitor abemaciclib?**
 - a. It occurs early in the course of treatment
 - b. It can be managed with loperamide and dose reductions
 - c. It usually requires permanent discontinuation of the drug
- 4. Which of the following statements is true regarding the CDK4/6 inhibitor palbociclib?**
 - a. It is administered on a continuous schedule
 - b. It is associated with more neutropenia than is abemaciclib
 - c. Both a and b